Osteocyte-derived Sclerostin Impairs Cognitive Function During Ageing and Alzheimer’s Disease Progression

Tianshu Shi,Siyu Shen,Yong Shi,Qianjin Wang,Guanqun Zhang,Jiaquan Lin,Jiang Chen,Feng Bai,Lei Zhang,Yangyufan Wang,Wang Gong,Xiaoyan Shao,Guiquan Chen,Wenjin Yan,Xiang Chen,Yuze Ma,Liming Zheng,Jianghui Qin,Ke Lu,Na Liu,Yun Xu,Yun Stone Shi,Qing Jiang,Baosheng Guo

DOI: https://doi.org/10.1038/s42255-024-00989-x

IF: 19.865

2024-01-01

Nature Metabolism

Abstract:Ageing increases susceptibility to neurodegenerative disorders, such as Alzheimer’s disease (AD). Serum levels of sclerostin, an osteocyte-derived Wnt–β-catenin signalling antagonist, increase with age and inhibit osteoblastogenesis. As Wnt–β-catenin signalling acts as a protective mechanism for memory, we hypothesize that osteocyte-derived sclerostin can impact cognitive function under pathological conditions. Here we show that osteocyte-derived sclerostin can cross the blood–brain barrier of old mice, where it can dysregulate Wnt–β-catenin signalling. Gain-of-function and loss-of-function experiments show that abnormally elevated osteocyte-derived sclerostin impairs synaptic plasticity and memory in old mice of both sexes. Mechanistically, sclerostin increases amyloid β (Aβ) production through β-catenin–β-secretase 1 (BACE1) signalling, indicating a functional role for sclerostin in AD. Accordingly, high sclerostin levels in patients with AD of both sexes are associated with severe cognitive impairment, which is in line with the acceleration of Αβ production in an AD mouse model with bone-specific overexpression of sclerostin. Thus, we demonstrate osteocyte-derived sclerostin-mediated bone–brain crosstalk, which could serve as a target for developing therapeutic interventions against AD.